160 studies found for:    "psoriatic arthritis"
Show Display Options
RSS Create an RSS feed from your search for:
"psoriatic arthritis"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of Psoriatic Arthritis
Conditions: Psoriasis;   Psoriatic Arthritis
Intervention:
2 Completed Metformin in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Metformin;   Drug: Placebo
3 Recruiting Psoriatic Arthritis Treat to Target vs. Usual Care
Condition: Psoriatic Arthritis (PsA)
Intervention: Other: Intensive Care
4 Completed TIght COntrol of Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Intensive management or Tight control;   Drug: Standard management - Control group
5 Completed
Has Results
REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Etanercept (Enbrel®)
Condition: Psoriatic Arthritis
Intervention: Drug: Etanercept
6 Completed Tumor Necrosis Factors (TNF)-α Blockade for Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Infliximab;   Drug: Etanercept
7 Active, not recruiting AMG 827 in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: AMG 827;   Drug: Placebo
8 Completed Effect of Exercise and Diet on Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Other: Diet;   Other: Exercise;   Other: Diet and Exercise;   Other: Healthy Lifestyle (Control) Group
9 Not yet recruiting Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Biological: Secukinumab
10 Completed Phase II Study With CC-10004 in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: CC-10004;   Drug: Matching Placebo
11 Completed Rituxan With or Without Methotrexate in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: Rituximab
12 Recruiting Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
Condition: Psoriatic Arthritis
Interventions: Drug: Tofacitinib;   Other: Placebo
13 Completed Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Biological: AIN457;   Biological: Placebo
14 Completed Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
Condition: Psoriatic Arthritis
Intervention:
15 Completed Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
Conditions: Psoriatic Arthritis;   Psoriasis
Intervention:
16 Recruiting A Study of Golimumab in Participants With Active Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Placebo;   Drug: Golimumab
17 Recruiting Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: 210 mg brodalumab;   Drug: 140 mg brodalumab;   Drug: Placebo
18 Completed
Has Results
Study Evaluating Etanercept on Skin and Joint Disease in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Intervention: Drug: etanercept
19 Recruiting Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: Etanercept + Oral Methotrexate;   Drug: Etanercept + Placebo for Methotrexate;   Drug: Oral Methotrexate + Placebo for Etanercept
20 Recruiting Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis
Condition: Psoriatic Arthritis
Interventions: Drug: UCB4940 40 mg;   Drug: UCB4940 80 mg;   Drug: UCB4940 160 mg;   Drug: UCB4940 240 mg;   Drug: UCB4940 320 mg;   Drug: UCB4940 560 mg;   Other: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years